WallStreetZenWallStreetZen

NYSEMKT: AEON
Aeon Biopharma Inc Earnings & Revenue

AEON earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$324.0M
Current Profit Margin
0%

AEON Return on Equity

Insufficient data to display

Be the first to know when AEON announces earnings.

AEON Return on Assets

Current Company
-3,676.5%
Current Industry
2.9%
AEON is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

AEON Return on Capital Employed

Current Company
5,221.7%
Current Industry
19.5%
AEON has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AEON vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AEON$0.00-$323.91M-$323.95MN/AN/A
COYA$6.13M-$9.55M-$10.30MN/AN/A
FGEN$167.49M-$214.56M-$240.46M-3.95%N/A
RLMD$0.00-$94.30M-$94.30MN/AN/A
ADAG$18.11M-$14.94M-$18.95M+64.33%N/A

Aeon Biopharma Earnings & Revenue FAQ

What were AEON's earnings last quarter?

Aeon Biopharma (NYSEMKT: AEON) reported Q4 2023 earnings per share (EPS) of -$10.07, up 3,928% year over year. Total Aeon Biopharma earnings for the quarter were -$374.24 million. In the same quarter last year, Aeon Biopharma's earnings per share (EPS) was -$0.25.

If you're new to stock investing, here's how to buy Aeon Biopharma stock.

What was AEON's earnings growth in the past year?

As of Q3 2024, Aeon Biopharma's earnings has grown year over year. Aeon Biopharma's earnings in the past year totalled -$323.95 million.

What was AEON's revenue last quarter?

Aeon Biopharma (NYSEMKT: AEON) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Aeon Biopharma's revenue was $0.00.

What was AEON's revenue growth in the past year?

As of Q3 2024, Aeon Biopharma's revenue has grown null year over year. Aeon Biopharma's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.